Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility
Cancers - Switzerland
doi 10.3390/cancers11060787
Full Text
Open PDFAbstract
Available in full text
Date
June 7, 2019
Authors
Publisher
MDPI AG